Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Sarcletti

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Lancet (London, England)|December 3, 1994
Differences in heterosexual transmission of HIV-1 and HIV-2J Möst, L Spötl, M Sarcletti, et al.
Journal of Chromatography. A|August 7, 2001
Capillary electrophoretic separation of protease inhibitors used in human immunodeficiency virus therapyW Gutleben, N D Tuan, H Stoiber, et al.
Clinical Nephrology|November 15, 2000
Pyuria in patients treated with indinavir is associated with renal dysfunctionM Sarcletti, A Petter, N Romani, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1994
Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activationR Zangerle, H Gallati, M Sarcletti, et al.
European Journal of Medical Research|November 19, 2002
Loss of zidovudine related mutations in the reverse transscriptase gene of HIV after switching therapyB Falkensammer, R El Attal, B Müllauer, et al.
International Archives of Allergy and Immunology|August 7, 1998
Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individualsR Zangerle, S Steinhuber, M Sarcletti, et al.
Brain, Behavior, and Immunity|February 12, 2008
Quality of life and immune activation in patients with HIV-infectionK Schroecksnadel, M Sarcletti, C Winkler, et al.
Clinical Immunology and Immunopathology|September 1, 1994
Increased concentrations of soluble tumor necrosis factor receptor 75 but not of soluble intercellular adhesion molecule-1 are associated with the decline of CD4+ lymphocytes in HIV infectionR Zangerle, D Fuchs, M Sarcletti, et al.
The Journal of General Virology|February 17, 2000
Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive womenA Petter, K Heim, M Guger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 2, 2015
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in EuropeL Marije Hofstra, Nicolas Sauvageot, Jan Albert, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Lancet (London, England)|December 3, 1994
Differences in heterosexual transmission of HIV-1 and HIV-2J Möst, L Spötl, M Sarcletti, et al.
Journal of Chromatography. A|August 7, 2001
Capillary electrophoretic separation of protease inhibitors used in human immunodeficiency virus therapyW Gutleben, N D Tuan, H Stoiber, et al.
Clinical Nephrology|November 15, 2000
Pyuria in patients treated with indinavir is associated with renal dysfunctionM Sarcletti, A Petter, N Romani, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1994
Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activationR Zangerle, H Gallati, M Sarcletti, et al.
European Journal of Medical Research|November 19, 2002
Loss of zidovudine related mutations in the reverse transscriptase gene of HIV after switching therapyB Falkensammer, R El Attal, B Müllauer, et al.
International Archives of Allergy and Immunology|August 7, 1998
Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individualsR Zangerle, S Steinhuber, M Sarcletti, et al.
Brain, Behavior, and Immunity|February 12, 2008
Quality of life and immune activation in patients with HIV-infectionK Schroecksnadel, M Sarcletti, C Winkler, et al.
Clinical Immunology and Immunopathology|September 1, 1994
Increased concentrations of soluble tumor necrosis factor receptor 75 but not of soluble intercellular adhesion molecule-1 are associated with the decline of CD4+ lymphocytes in HIV infectionR Zangerle, D Fuchs, M Sarcletti, et al.
The Journal of General Virology|February 17, 2000
Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive womenA Petter, K Heim, M Guger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 2, 2015
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in EuropeL Marije Hofstra, Nicolas Sauvageot, Jan Albert, et al.
Pageof 2